We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Verona Pharma

News List

Enrol call: Verona recruits 800 patients for COPD trial pharmatimes
January 24, 2022
The phase 3 trial involved over 800 candidates to assess ensifentrine when administered as a maintenance therapy to patients diagnosed with COPD.
Verona Pharma launches late-stage COPD trial programme pharmatimes
September 27, 2020
Verona Pharma has initiated phase III trials to evaluate the safety and efficacy of nebulised ensifentrine in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD).
Inhaled ensifentrine will be assessed in hospitalised patients pharmatimes
September 08, 2020
Verona Pharma has kicked off a pilot study to investigate the efficacy and safety of ensifentrine delivered via pressurised metered-dose inhaler (pMDI) formulation in patients hospitalised with COVID-19.
Verona progresses PhII trial of COPD inhaler pharmatimes
August 19, 2020
Verona Pharma is progressing a Phase II trial of new inhaler formulation of ensifentrine following a coronavirus pandemic-induced pause.
Verona Pharma begins dosing RPL554 in Phase IIb COPD trial pharmatimes
July 27, 2017
Patients have begun receiving Verona Pharma’s experimental respiratory drug RPL554 in a Phase IIb trial assessing its potential as a maintenance therapy for chronic obstructive pulmonary disease